Table 1 Baseline patient characteristics in three cohorts of metastatic prostate cancer
From: Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer
Baseline Characteristic | mCRPC pre-ARSI (n = 10) | mCRPC post-ARSI (n = 10) | mHSPC starting ADT (n = 10) | Total (n = 30) |
|---|---|---|---|---|
Age | ||||
 Median (range) | 74 (51–83) | 72 (53–88) | 72 (55–82) | 72 (51–88) |
Race | ||||
 White | 9 (90%) | 9 (90%) | 8 (80%) | 26 (87%) |
 Black or African American | 0 (0%) | 0 (0%) | 2 (20%) | 2 (7%) |
 Other | 1 (10%) | 1 (10%) | 0 (0%) | 2 (6%) |
PSA (ng/mL) | ||||
 Median (range) | 7 (2–1327) | 27 (5–126) | 90 (4.3–1427) | 32 (2–1427) |
Hemoglobin (g/dL) | ||||
 Median (range) | 12.2 (7.9–14.3) | 12.2 (9.4–14.1) | 13.6 (8.5–16.2) | 12.6 (7.9–16.2) |
  < 13.7 g/dL (LLN) | 9 (90%) | 8 (80%) | 5 (50%) | 22 (73%) |
LDH (U/L) | ||||
 Median (range) | 238 (142–517) | 224 (117–330) | 193 (142–230) | 224 (117–517) |
  > 100 U/L (ULN) | 3 (30%) | 7 (70%) | 4 (40%) | 14 (47%) |
Alkaline phosphatase (U/L) | ||||
 Median (range) | 83 (44–877) | 87 (41–207) | 111 (43–1378) | 96 (41–1378) |
  > 110 U/L (ULN) | 4 (40%) | 3 (30%) | 5 (50%) | 12 (40%) |
Prior Chemotherapy | ||||
 Cabazitaxel | 0 (0%) | 2 (20%) | 0 (0%) | 2 (7%) |
 Docetaxel | 3 (30%) | 5 (50%) | 0 (0%) | 8 (27%) |
Metastatic Site | ||||
  Bone | 8 (80%) | 10 (100%) | 9 (90%) | 27 (90%) |
  Lymph Nodes (Inside Pelvis) | 5 (50%) | 3 (30%) | 7 (70%) | 15 (50%) |
  Lymph Node (Outside Pelvis) | 4 (40%) | 4 (40%) | 4 (40%) | 12 (40%) |
  Liver | 0 (0%) | 1 (10%) | 0 (0%) | 1 (3%) |
  Lung | 2 (20%) | 1 (10%) | 0 (0%) | 3 (10%) |
Gleason Grade, Score (sum) | ||||
  < 6 | 1 (10%) | 1 (10%) | 1 (10%) | 3 (10%) |
 7 | 3 (30%) | 3 (30%) | 1 (10%) | 7 (23%) |
 8–10 | 5 (50%) | 6 (10%) | 6 (60%) | 17 (57%) |
 Missing | 1 (10%) | 0 (0%) | 2 (20%) | 3 (10%) |